Gabapentin carries an FDA warning about suicidal thoughts, but the actual measured risk is extremely small. In clinical trials totaling nearly 5,000 patients, only two people on gabapentin and one on placebo experienced suicidal ideation. That translates to roughly 0.28 additional cases per 1,000 patients compared to a sugar pill. The warning exists not because gabapentin stands out as especially dangerous, but because the FDA applied a blanket alert to an entire class of seizure medications in 2008.
What the FDA Warning Actually Says
In January 2008, the FDA reviewed 199 clinical trials covering 11 different antiepileptic drugs, including gabapentin, and found a small but statistically measurable increase in suicidal thoughts and behavior across the class. The agency then required all these medications to carry the same warning label, regardless of how each individual drug performed in the data. For gabapentin specifically, the numbers were vanishingly small: three total events of suicidal ideation across all trials, split two-to-one between the drug and placebo groups. Some researchers have questioned whether this blanket approach was warranted, calling it potentially more alarming than the evidence supports.
What Recent Research Shows
A large population-based study published in The BMJ looked at gabapentinoids (gabapentin and its close relative pregabalin) and the risk of self-harm. The findings paint a more nuanced picture than a simple cause-and-effect relationship. Patients who were prescribed gabapentinoids already had an elevated risk of self-harm before they ever started the medication. That elevated risk persisted during the early phase of treatment and rose again shortly after stopping the drug.
This pattern suggests the link between gabapentin and suicidal thoughts may have more to do with the conditions it treats, like chronic pain and anxiety, than with the drug itself. Chronic pain in particular is independently associated with depression and suicidal ideation. The researchers concluded their findings do not support a direct effect of gabapentinoid treatment on self-harm, but they emphasized that patients should be monitored throughout treatment.
How Gabapentin Affects the Brain
Despite its name suggesting a connection to GABA, the brain’s main calming chemical, gabapentin doesn’t actually work on GABA receptors. Instead, it binds to a specific part of calcium channels that are found throughout the brain and spinal cord. By reducing calcium flow into nerve cells, it dials down the overactive signaling that causes seizures, nerve pain, and certain types of anxiety. Because these calcium channels are so widespread in the brain, gabapentin’s effects can extend beyond pain and seizures into mood and behavior, which likely explains why some people notice emotional changes on the drug.
Behavioral Changes to Watch For
While suicidal thoughts are rare, subtler mood and behavioral shifts are more commonly reported. These can include irritability, agitation, restlessness, hostility, feeling unusually sad or hopeless, and getting upset more easily than usual. Some people describe a false sense of well-being or rapidly changing moods. These symptoms can appear even after stopping the medication, not just while taking it.
Children and adolescents seem particularly prone to behavioral side effects. In younger patients, gabapentin has been associated with aggressive behavior, concentration problems, hyperactivity, crying spells, and emotional overreactivity. These changes can show up as declining school performance or sudden personality shifts that parents and teachers notice before the child does.
In one documented case, an adult patient started on gabapentin for pain experienced progressive personality changes over four weeks as his dose was gradually increased. Both he and his partner noticed increasing depression and aggression, which they attributed to the medication. His mood continued to deteriorate until he attempted suicide. Cases like this, while rare, illustrate how the changes can build gradually rather than appearing all at once.
When Symptoms Are Most Likely
The highest-risk windows appear to be the early weeks of treatment, particularly as the dose is being increased, and the period immediately after stopping the drug. The BMJ study specifically noted that the risk of self-harm was elevated during the initial phase of treatment and again shortly after discontinuation. This pattern makes the first month or so worth paying close attention to, especially if you’re adjusting doses.
If you notice mood changes and want to stop taking gabapentin, don’t quit abruptly. Stopping suddenly can trigger withdrawal symptoms within 24 to 48 hours, including agitation, confusion, tremor, rapid heartbeat, and insomnia. The standard recommendation is to taper off over at least one week. Withdrawal-related distress could compound any existing mood problems, so a gradual reduction is safer than going cold turkey.
Who Faces Higher Risk
The people most likely to experience mood-related side effects from gabapentin are often those who were already vulnerable before starting the drug. If you have a history of depression, anxiety, or suicidal thoughts, the background risk is higher to begin with. People taking gabapentin for chronic pain may be especially susceptible, since long-term pain itself is a significant driver of depression and suicidal ideation. The challenge is separating the effects of the drug from the effects of the condition it’s treating.
The practical takeaway is straightforward: the absolute risk of gabapentin directly causing suicidal thoughts is very low based on clinical trial data. But the medication is frequently prescribed to people whose underlying conditions already put them at elevated risk. Paying attention to mood changes in the first few weeks, during dose adjustments, and after stopping the drug gives you the best chance of catching a problem early. If you or someone close to you notices increasing hopelessness, agitation, or thoughts of self-harm, that warrants a prompt conversation with the prescribing doctor about whether to adjust or discontinue the medication.